Announcements Trials
Browse Landscape

Phase

Phase 2 43Phase 3 34Phase 1 6Phase NA 3Phase 4 2Phase 2/3 2Phase 1/2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Prostatic Neoplasms 3Breast Neoplasms 2Stage I Prostate Adenocarcinoma AJCC v7 1Neoplasms 1Neoplasm Metastasis 1Castration-resistant Prostate Cancer Patients with Oligometastases 1Breast Diseases 1

Interventions

Capecitabine 16Paclitaxel 12Docetaxel 10Cyclophosphamide 10Epirubicin 8Gemcitabine 7Letrozole 6Doxorubicin 6Carboplatin 6Trastuzumab 5Vinorelbine 4Cisplatin 4pertuzumab 3exemestane 3Neoadjuvant Therapy 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3130-nm albumin-bound paclitaxel 3apatinib 2Zoledronic Acid 2Thiotepa 2Taxes 2Tamoxifen 2Standard of Care 2Radiosurgery 2Melatonin 2Lapatinib 2Injections 2Goserelin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Breast Neoplasms × Goserelin × Clear all
NCT05253066 2022-02-23

Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

Shengjing Hospital

Phase 2/3 Unknown
130 enrolled
Breast

Breast Neoplasms

NCT03373708 2017-12-18

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Shandong Cancer Hospital and Institute

Phase 2/3 Unknown
200 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡